Simvastatin induces death of multiple myeloma cell lines

Journal of Investigative Medicine

Volumn 52, Issue 5, 2004, Pages 335-344

  Gronich, Naomi ^a   Drucker, Liat ^a   Shapiro, Hava ^a   Radnay, Judith ^a   Yarkoni, Shai ^a   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Apoptosis; Calcium; Interleukin 6; Myeloma; Simvastatin

Indexed keywords

CALCIUM ION; INTERLEUKIN 6; PROTEIN TYROSINE KINASE; RAS PROTEIN; SIMVASTATIN; STATINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRUG EXPOSURE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IC 50; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN PHOSPHORYLATION;

EID: 7444259081     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-05-34     Document Type: Article

References (62)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
2. Nakanishi M, Goldstein JL, Brown MS. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 1988; 263:8929-37.
3. Maltese WA, Sheridan KM. Isoprenoid synthesis during the cell cycle. Studies of 3-hydroxy-3-methylglutaryl-coenzyme A synthase and reductase and isoprenoid labeling in cells synchronized by centrifugal elutriation. J Biol Chem 1988; 263:10104-10.
4. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med 2000;32:164-76.
5. Wong W-W, Dimmitroulakos J, Minden M, Penn L. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19.
6. Quensery-Huneeus V, Galick HA, Siperstein MD, et al. The dual role of mevalonate in cell cycle. J Biol Chem 1983;258: 378-85.
7. Hoffman M. Playing tag with membrane proteins. Science 1991;254:650-1.
8. Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol 1996;22:197-212.
9. Habenicht AJ, Glonset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980;255:5134-40.
10. Morris TJ, Palm SL, Pena J, et al. Inhibition of hepatoma tissue culture growth by lovastatin. A novel chemotherapeutic strategy. Surg Forum 1991;42:952-4.
11. Takobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle specific effects of lovastatin. Proc Natl Acad Sci U S A 1980;77:3957-61.
12. Maltese WA, Sheridan KN. Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate relation of neuritic outgrowth and acetylcholinesterase activity to changes in cell proliferation and blocked isoprenoid synthesis. J Cell Physiol 1985;125:540-58.
13. Newman A, Clutterbuck RD, Powles RL, et al. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997;24:533-7.
14. Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994;205: 1681-7.
15. Marcelli M, Cummingham GR, Haiacher SJ, et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998;58:76-83.
16. Diamond AM, Jaffe D, Murray JL, et al. Lovastatin effects on human breast carcinoma cells. Differential toxicity of an Adriamycin-resistant derivative and influence on selenocysteine tRNAS. Biochem Mol Biol Int 1996;38:345-55.
17. Dimmitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93: 1308-18.
18. Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Invest Med 2001;49:319-24.
19. Waddick KG, Uckun FM. Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Biochem Pharmacol 1998;56:1411-26.
20. Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 2000; 267:536-40.
21. Diomede L, Albani D, Sottocorno M, et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-32.
22. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
23. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002;16:1362-71.
24. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (ST1571, Gleevec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukemia. Br J Cancer 2003;89:1855-9.
25. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19.
26. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992;339:1154-6.
27. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 1999;221:294-311.
28. Kawata S, Takaishi K, Nasage T, et al. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990;50: 3270-3.
29. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 1991;32:1237-52.
30. Vitols S, Norgren S, Juliusson G, et al. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994;84:2689-98.
31. Hentosh P, Yuh SH, Elson CE, Peffley DM. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 2001;32:154-66.
32. Wong W-W, Dimmitroulakos J, Minden M, Penn L. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19.
33. Shipman CM, Croucher PI, Russell GG, et al. The bisphosphonate Incadronate (YM175) causes apoptosis of human myeloma cells in vivo by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
34. Xia Z, Tan MM, Wong WWL, et al. Blocking protein geranyl-geranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15: 1398-407.
35. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA redutase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1 beta interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000;67:863-76.
36. Keyomarsi K, Sanoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9.
37. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 1997; 57:604-9.
38. Lee SJ, Ha MJ, Lee J, et al. Inhibition of the 3-hydroxy-3-methylglutaryl coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/ CIP1) in human prostate carcinoma cells. J Biol Chem 1998;273:10618-23.
39. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17: 2393-402.
40. Loubat A, Rochet N, Turchi L, et al. Evidence for a p23 caspase-cleaved form of p27(KIP1) involved in G1 arrest. Oncogene 1999;18:3324-33.
41. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-97.
42. Soma MR, Baetta R, De Remzis MR, et al. In vivo enhanced antitumor activity of carmustine [N,Nw-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 1995;55:597-602.
43. Lamprecht J, Wojcik C, Jakobisiak M, et al. Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol Int 1999;23:51-60.
44. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int Oncol 1998;12:717-23.
45. Hung KS, Hong CY, Lee J, et al. Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Biochem Biophys Res Commun 2000;269:718-25.
46. Sane AT, Betrand R. Caspase inhibtion in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res 1999;59:3565-9.
47. Dvorakova K, Waltmire CN, Payne CM, et al. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001;97:3544-51.
48. 6(3), acts as a mitochondrial probe in human neutrophils. Biochem Biophys Res Commun 1982;108:1495-501.
49. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-72.
50. LeMasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochem Biophys Acta 1998;1366:177-96.
51. Plotkowski MC, Povoa HCC, Zahm JM, et al. Early mitochondrial dysfunction, superoxide anion production, and DNA degredation are associated with non-apoptotic death of human airway epithelial cells induced by Pseudomonas aeruginosa exotoxin A. Am J Respir 2002;26:617-26.
52. Ferlin M, Noraz N, Hertogh C, et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6- independent transduction pathway. Br J Hematol 2000;111:626-34.
53. Meroni PL, Raschi E, Testoni C, et al. Stalins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-8.
54. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-61.
55. Gooding RP, Bybee A, Cooke F, et al. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Hematol 1999;106:669-81.
56. Akira S, Isshiki H, Nakajima T, et al. Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Found Symp 1992;167:47-62.
57. Santhanam U, Ghrayeb J, Sehgal PB, May LT. Posttranslational modifications of human interleukin-6. Arch Biochem Biophys 1998;274:161-70.
58. Semenov I, Akyuz C, Roginskaya V, et al. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 2002;26:271-80.
59. Squier MKT, Miller ACK, Malkinson AM, Cohen JJ. Calpain activation in apoptosis. J Cell Physiol 1994;159:229-37.
60. Haag H, Grunberg B, Weber C, et al. Lovastatin inhibits receptor-stimulated Ca(2+)-influx in retinoic acid differentiated U937 and HL-60 cells. Cell Signal 1994;6:735-42.
61. Clunn GF, Lymn JS, Schachter M, Hughes AD. Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells. Br J Pharmacol 1997;121:1789-95.
62. ++ release and vascular reactivity. J Cardiovasc Pharmacol 1999;34:95-101.